First-line use of Pfizer’s Bosulif cleared in the US
Pfizer’s Bosulif has been approved in the US to treat patients with newly-diagnosed Ph+ chronic myelogenous leukemia.
Read More
Tag: Bosulif
Pfizer, Avillion file for Bosulif expansion
Pfizer and Avillion have filed applications on both sides of the Atlantic seeking to expand the treatment scope of chronic myeloid leukaemia therapy Bosulif.
Read More
NICE expands NHS treatment options for CML, lung cancer
The National Institute for Health and Care Excellence has published two sets of guidelines increasing the treatment options for NHS patients with chronic myeloid leukaemia and non-small cell lung cancer.
Read More
NICE backs Pfizer’s Bosulif for CML
NHS use of Pfizer’s Bosulif is being endorsed by the National Institute for Health and Care Excellence to treat some patients with chronic myeloid leukaemia, in a move which, if confirmed in final guidelines, could significantly widen access to the drug.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
